SK bioscience does not enter into transactions or contracts that transfer income between countries to take advantage of differences in tax laws or loopholes in the international tax system, and ensures that taxable income is distributed consistently with the value created in each country where it operates. SK bioscience does not use tax havens that unreasonably reduce the tax burden and faithfully fulfill tax obligations in international transactions through a healthy tax structure.

For transactions with special parties, SK bioscience follows the OECD’s Guideline for Transfer Pricing and the laws and regulations of each country as a rule for transactions. For transfer pricing transactions with overseas special parties, we prepare the BEPS report and the pricing report with external tax experts to manage the implementation.

SK bioscience complies with national and international laws and regulations by evaluating and managing tax risks that may occur during business activities such as new investments for growth, etc. However, given the complexity of tax laws and differences in their interpretation, we understand that it would not be feasible to eliminate all tax risks. Focusing on the proactive detection and identification of uncertain tax-related issues, we are closely cooperating with tax professionals to actively communicate with the taxing authorities.

The company's tax officers and employees faithfully fulfill their tax reporting and payment obligations in accordance with relevant laws and regulations in a transparent relationship with the tax authorities